Ranibizumab long-term observational data presented

Article

Long-term observational data presented at the 2014 European Society of Retina Specialists (EURETINA) conference support the safety and efficacy profile of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab (Lucentis, Novartis) for the treatment of appropriate patients across its indications

Long-term observational data presented at the 2014 European Society of Retina Specialists (EURETINA) conference support the safety and efficacy profile of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab (Lucentis, Novartis) for the treatment of appropriate patients across its indications.

Ranibizumab is licensed and approved by the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) across four ophthalmic indications: wet age-related macular degeneration (AMD), visual impairment caused by diabetic macular oedema (DME), visual impairment caused by macular oedema secondary to branch or central retinal vein occlusion (BRVO and CRVO), and visual impairment caused by choroidal neovascularization (CNV) secondary to pathological myopia. The data at EURETINA 2014 were presented by Novartis.

One-year follow-up data from 2,112 wet AMD patients enrolled in the LUMINOUS trial showed that wet AMD patients with prior ranibizumab treatment had better visual acuity and a lower central retinal thickness at baseline when compared to patients with no prior ranibizumab treatment.

At 12 months, wet AMD patients achieved good visual acuity outcomes, with patients who had prior ranibizumab treatment generally maintaining their higher level of baseline visual acuity (-1.1 letters) and the patients with no prior ranibizumab treatment gaining 4.1 letters. Patients experienced relatively low numbers of monitoring visits (approximately 7.5) and an average of 5.2 injections.

A second report including more than 10,000 patients enrolled in the LUMINOUS study also showed a higher mean baseline visual acuity in patients previously treated with ranibizumab compared to patients with no prior ranibizumab treatment across all indications:

  • Wet AMD: 55.6 letters for prior treated patients; 46.4 letters for treatment-naïve patients
  • DMO: 55.3 letters for prior treated patients; 40.8 letters for treatment-naïve patients
  • BRVO: 52.9 letters for prior treated patients; 37.3 letters for treatment-naïve patients
  • CRVO: 45.2 letters for prior treated patients; 38.9 letters for treatment-naïve patients.

"The new ranibizumab studies presented at EURETINA further support a wealth of data which is already available on the safety and efficacy of ranibizumab from clinical trials," said Frederic Guerard, managing director, UK and Ireland, Novartis Pharmaceuticals UK Ltd. "The ongoing LUMINOUS study will provide long-term observational data on ranibizumab from routine clinical practice across all of its licensed indications… and the information that the LUMINOUS study generates will enable clinicians to provide better care for their patients on a personalized basis and ultimately optimize outcomes."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
Related Content
© 2025 MJH Life Sciences

All rights reserved.